{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:36:24Z","timestamp":1776184584562,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.hlc.2010.07.005","type":"journal-article","created":{"date-parts":[[2010,8,22]],"date-time":"2010-08-22T04:38:42Z","timestamp":1282451922000},"page":"595-600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Endothelin Receptor Antagonists are an Effective Long Term Treatment Option in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease With or Without Trisomy 21"],"prefix":"10.1016","volume":"19","author":[{"given":"F.D.","family":"Kermeen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Franks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Seale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Radford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2010.07.005_bib0005","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ahj.2005.07.005","article-title":"Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy","volume":"150","author":"Schulze-Neick","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.hlc.2010.07.005_bib0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/pcad.2002.127492","article-title":"Eisenmenger's syndrome: current management","volume":"45","author":"Berman","year":"2002","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.hlc.2010.07.005_bib0015","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/01.CIR.99.14.1858","article-title":"Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects","volume":"99","author":"Rosenzweig","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2010.07.005_bib0020","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.1016\/j.jacc.2004.02.033","article-title":"Pathologic assessment of vasculopathies in pulmonary hypertension","volume":"43","author":"Pietra","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2010.07.005_bib0025","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/eurheartj\/ehl116","article-title":"Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case\u2013control study","volume":"27","author":"Diller","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2010.07.005_bib0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Gali\u00e8","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2010.07.005_bib0040","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/hrt.2004.051961","article-title":"Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease","volume":"91","author":"Apostolopoulou","year":"2005","journal-title":"Heart"},{"issue":"Suppl. 3","key":"10.1016\/j.hlc.2010.07.005_bib0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2362.2006.01685.x","article-title":"Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects","volume":"36","author":"Sitbon","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.hlc.2010.07.005_bib0050","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.amjcard.2009.01.021","article-title":"Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome","volume":"103","author":"Duffels","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hlc.2010.07.005_bib0055","first-page":"196","article-title":"A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease","volume":"91","author":"Durongpisitkul","year":"2008","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.hlc.2010.07.005_bib0060","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/hrt.2006.100388","article-title":"Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study","volume":"93","author":"Apostolopoulou","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.hlc.2010.07.005_bib0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.amjcard.2004.03.081","article-title":"Initial experience with bosentan therapy in patients with the Eisenmenger syndrome","volume":"94","author":"Christensen","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hlc.2010.07.005_bib0070","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1136\/hrt.2006.097360","article-title":"Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect","volume":"93","author":"D\u2019Alto","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.hlc.2010.07.005_bib0075","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/hrt.2006.089185","article-title":"Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease","volume":"93","author":"Diller","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.hlc.2010.07.005_bib0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijcard.2007.04.078","article-title":"Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study","volume":"127","author":"Gatzoulis","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hlc.2010.07.005_bib0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2004.08.025","article-title":"Safety and tolerability of bosentan in adults with Eisenmenger physiology","volume":"98","author":"Gatzoulis","year":"2005","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hlc.2010.07.005_bib0090","first-page":"415","article-title":"An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease","volume":"13","author":"Ibrahim","year":"2006","journal-title":"Can Respir J"},{"key":"10.1016\/j.hlc.2010.07.005_bib0095","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1017\/S1047951106000114","article-title":"Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease","volume":"16","author":"Kotlyar","year":"2006","journal-title":"Cardiol Young"},{"key":"10.1016\/j.hlc.2010.07.005_bib0100","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1053\/euhj.1998.1046","article-title":"Eisenmenger syndrome. Factors relating to deterioration and death","volume":"19","author":"Daliento","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2010.07.005_bib0105","unstructured":"Actelion Pharmaceuticals Australia Pty Limited. Tracleer\u00ae (bosentan) Product Information 2007. TGA approved 30, November, 2007."},{"key":"10.1016\/j.hlc.2010.07.005_bib0110","first-page":"919","article-title":"The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure","volume":"132","author":"Guyatt","year":"1985","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.hlc.2010.07.005_bib0115","unstructured":"Rich S. Primary pulmonary hypertension: executive summary from the World Symposium on Primary Pulmonary Hypertension, Evian, France; 1998."},{"key":"10.1016\/j.hlc.2010.07.005_bib0120","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.hlc.2010.07.005_bib0125","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2010.07.005_bib0130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1378\/chest.124.1.247","article-title":"Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study","volume":"124","author":"Sitbon","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.hlc.2010.07.005_bib0135","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2010.07.005_bib0140","article-title":"Down patients with Eisenmenger syndrome: is bosentan treatment an option?","author":"Duffels","year":"2008","journal-title":"Int J Cardiol"},{"issue":"Suppl. 3","key":"10.1016\/j.hlc.2010.07.005_bib0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2362.2006.01682.x","article-title":"Bosentan in Eisenmenger syndrome and chronic thromboembolic pulmonary hypertension","volume":"36","author":"Kourouklis","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.hlc.2010.07.005_bib0150","first-page":"100","article-title":"Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome","volume":"15","author":"Hopkins","year":"1996","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.hlc.2010.07.005_bib0155","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0002-9149(02)03328-3","article-title":"Usefulness of epoprostenol therapy in the severely ill adolescent\/adult with Eisenmenger physiology","volume":"91","author":"Fernandes","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hlc.2010.07.005_bib0160","doi-asserted-by":"crossref","unstructured":"Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Heart 2008; 94(Suppl. 1): i1\u201341.","DOI":"10.1136\/hrt.2007.132118"},{"key":"10.1016\/j.hlc.2010.07.005_bib0165","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2165\/00003495-200868080-00004","article-title":"Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome","volume":"68","author":"Galie","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.hlc.2010.07.005_bib0170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.healun.2006.11.009","article-title":"Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan","volume":"26","author":"Keogh","year":"2007","journal-title":"J Heart Lung Transplant"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950610014083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950610014083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T17:57:01Z","timestamp":1761415021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950610014083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S1443950610014083"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2010.07.005","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endothelin Receptor Antagonists are an Effective Long Term Treatment Option in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease With or Without Trisomy 21","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2010.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2010 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}